|Bid||21.69 x 1000|
|Ask||21.69 x 900|
|Day's Range||20.92 - 21.81|
|52 Week Range||12.77 - 38.00|
|Beta (3Y Monthly)||3.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.11|
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the third quarter ended September 30, 2018 on Tuesday, November 6, 2018, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Tuesday, November 6, 2018, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 3659459).
The SPDR Biotech ETF ( XBI) had been up 18% for 2018 at the start of September. Since then the Biotech ETF has given up nearly all of its gains and is now up less than 1% on the year. But not all biotechs have been poor performers during this time, and some may be poised to gain 15% or more in the final few weeks of 2018. The stock reached an intraday high of $23.50 on October 18, and should the stock be able to rise above technical resistance at $24, it could be on its way to $27.20. Should the stock rise above technical resistance at $45.25, the shares could increase to roughly $50.
How Is Acadia Pharmaceuticals Positioned Now? Acadia Pharmaceuticals’ (ACAD) Nuplazid generated revenues of $57.1 million in the second quarter of 2018 compared to $30.5 million in the second quarter of 2017, reflecting an ~87% YoY (year-over-year) growth. After the second quarter of 2018, Acadia Pharmaceuticals lowered its sales revenue guidance for Nuplazid to $210 million–$255 million for fiscal 2018.
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.
NEW YORK, NY / ACCESSWIRE / October 12, 2018 / U.S. equities remained bearish on Thursday as worries over rising interest rate and sell-off in technology shares pressure major markets to lower. The Dow ...
The FDA issued a positive statement on the company's drug for Parkinson's disease psychosis, but investors still need to watch one important metric.
There has been no shortage of encouraging news over the past few months across the biotech sector, but the patterns that are appearing on several key charts are suggesting that the story could be in the early stages of shifting. Active traders who are looking for exposure to biotechnology often turn to exchange-traded products such as the SPDR S&P Biotech ETF. As you can see from the chart below, the price has been trading along a well-defined trendline over the past couple of years, but the recent close below the trendline suggests that the ETF is in the early stages of a downtrend.
Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018, which reflected ~6% year-over-year (or YoY) growth. Portola Pharmaceuticals’ net revenues grew from $8.92 million in the first half of 2018 to $10.66 million in the first half of 2017, reflecting ~20% YoY growth.
In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).
Technical analysis suggests that Acadia Pharmaceuticals Inc. ( ACAD), BeiGene Ltd. ( BGNE) and Intercept Pharmaceuticals Inc. ( ICPT) are three such stocks that could see the significant gains. Acadia shares have skyrocketed higher over the past few weeks and are trading around a technical resistance level at $21.50. Should the stock be able to rise above that level of resistance, the shares could rally by 13% to a price of $24, from its current price of around $21.40.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) with a market-capitalization of US$2.48b, rarely draw their attention. Despite this, commonly overlooked Read More...
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...
Today, Amarin Corporation stock is trading at $13.77, versus yesterday’s closing price of $12.40, reflecting ~11.05% growth. On September 24, Amarin’s stock price grew 314.7% to reach $12.40, versus $2.99 on September 21.
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 9:45 a.m. Eastern Time in New York City. ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Below is a list of names for those charts we believe are showing technical characteristics of either bullish or bearish reversal patterns that occurred over the past week. Bullish reversals imply institutional accumulation and the potential for higher prices.
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / U.S. markets were mixed on Friday, with the Dow Jones managing to close at an all-time high despite a plunge in technology and internet stocks. The Dow Jones Industrial Average gained 0.32 percent to close at 26,743.50, while the S&P 500 Index declined 0.04 percent to close at 2,929.67. The Nasdaq Composite Index decreased 0.51 percent to close at 7,986.96.
Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.